Phase II study of bortezomib (VELCADE) with cisplatin as first line treatment of malignant mesothelioma.

Trial Profile

Phase II study of bortezomib (VELCADE) with cisplatin as first line treatment of malignant mesothelioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2013

At a glance

  • Drugs Bortezomib (Primary) ; Cisplatin (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2013 Planned end date changed from 1 Dec 2009 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 11 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jan 2008 The expected completion date for this trial is now 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top